In addition to its function as a suppressor of pediatric kidney cancer (Wilms' tumor, nephroblastoma) (1, 2) the Wt1 protein also plays a role in normal human hematopoiesis and in leukemia. During hematopoiesis, Wt1 is expressed in a small subset of dormant cells, as well as in lineage-committed progenitor cells, but it is not detectable in mature blood cells (3) (4) (5) (6) . Fetal liver cells from embryonic mice lacking Wt1 (C57/B6 Wt1
) have an ϳ75% reduction in erythroid blast-forming units (BFU-Es), erythroid colony-forming units (CFU-Es), and colony-forming unit-granulocyte macrophage-erythroidmegakaryocyte (CFU-GEMM) (7) . Furthermore, forced expression of Wt1 by retroviral infection induced myelomonocytic differentiation of CD34 ϩ human hematopoietic progenitors and quiescence of a subset of immature CD38 Ϫ /CD34 ϩ cells (8) . In murine 32D cl3 cells, which differentiate in response to granulocyte colonystimulating factor (G-CSF), expression of Wt1 also resulted in an accelerated differentiation (9) . The proposed role of Wt1 in murine hematopoiesis was challenged by a recent study detecting no significant differences between the clonogenic potential of hematopoietic progenitor cells from the aorta-gonad-mesonephros (AGM) region of wild-type (Wt1 ϩ/ϩ ) and Wt1-null (Wt1 Ϫ/Ϫ ) embryos (10) . Although the reasons for these partly controversial results remain to be resolved, valuable evidence of the function of Wt1 during hematopoiesis can be obtained from the identification of its downstream target genes in hematopoietic precursor cells.
The Wt1 gene encodes zinc finger proteins, which can function as both transcription factors and post-transcriptional regulators. Among the four alternative Wt1 splice variants, insertion of a lysine-threonine-serine (ϩKTS) tripeptide between the third and fourth zinc finger reduces the DNA binding affinity of Wt1 protein (11, 12) . The Wt1(ϩKTS) forms presumably fulfill a role in RNA processing (13) , whereas Wt1 molecules without the KTS 1 These authors contributed equally to this work. 2 Correspondence: Department of Neonatology, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, D-13353 Berlin, Germany. E-mail: christof.dame@charite.de doi: 10.1096/fj.07-097576 splice insertion, Wt1(ϪKTS), interact with GC-and TCrich DNA sequences and function as transcription factors (14) . Expression of Wt1 is highest in the developing embryo, where it is detected in a limited set of tissues, predominantly in progenitor cells residing within the genitourinary system (15) . Direct proof that Wt1 is necessary for embryonic development came from gene-targeting experiments in mice. Mouse embryos with inactivation of both Wt1 alleles are usually lethal around midgestation and exhibit a predominant feature with the lack of kidneys and gonads (16) , in addition to defects in the development of the spleen (17) and the nervous system (18, 19) . The molecular mechanisms by which the transcription factor Wt1(ϪKTS) regulates hematopoietic differentiation are not fully understood. Such mechanisms may involve a direct effect on target genes in hematopoietic progenitor cells and/or the interaction with other proteins (20, 21) . Focusing on the implication of Wt1 in erythropoiesis, we reported recently that Wt1 activates transcription of the erythropoietin (Epo) gene in fetal mouse liver (22) . It is therefore conceivable that impaired expression of the major hematopoietic growth factor Epo may contribute to a compromised hematopoiesis in Wt1 deficiency. However, the report of a reduced in vitro proliferative capacity of Wt1 Ϫ/Ϫ early erythroid progenitors, in particular, of BFU-E and CFU-E (8) , points rather to a cell-autonomous defect. Such defect may include a diminished expression of hematopoietic growth factor receptors in the absence of Wt1.
The Epo receptor (EpoR) is essential for the development of 'definitive' hematopoiesis, as indicated by the intrauterine death of mice with homozygous deletion of the EpoR gene (EpoR Ϫ/Ϫ ) between day e10.5 and e13.5. In vitro, Epo binding to the EpoR contributes to the commitment of hematopoietic precursors (CFU-GEMM) to the erythroid lineage and the differentiation of BFU-E to CFU-E. At later stages, the EpoR is crucial for the survival of CFU-E progenitors and their terminal differentiation (23, 24) . EpoR expression can be regulated at the transcriptional and post-transcriptional level and by post-translational modification (25) (26) (27) . At the level of transcription, EpoR mRNA expression is controlled by positive and negative cis-regulatory elements that are located upstream of the EpoR gene. A minimal EpoR promoter element has been identified in the 5Ј-untranslated region (UTR) between the nucleotides (nt) Ϫ76 and nt ϩ 33, relative to the transcription start site (28) . As previously shown, the GC-rich EpoR promoter, which does not contain a TATA box, can be trans-activated by the hematopoietic transcription factor GATA-1 and the ubiquitously expressed Sp1 protein (29 -31) . Interestingly, our sequence inspection revealed several predicted binding motifs for Wt1 (GnGGGnGnG) in highly conserved regions of the EpoR promoter. In view of the above, and to clarify the role of Wt1 in murine hematopoiesis, we examined the hypothesis that the EpoR gene could be a molecular downstream target of the Wt1 transcription factor.
MATERIALS AND METHODS

Animals
Mouse breeding pairs (C57BL/6 strain) with heterozygous Wt1 deletion (Wt1 ϩ/Ϫ ) were originally obtained from the Jackson Laboratory (Bar Harbor, ME, USA) and mated in compliance with legal authorities. The embryos were collected at the indicated time points [morning of vaginal plug was considered embryonic day (e) 0.5] and genotyped by polymerase chain reaction (PCR) (18) .
Cell culture
Human hepatoma-derived HepG2 cells (ATCC HB-8065) and human embryonic kidney (HEK) 293 cells (ACC 305) were purchased from the American Type Culture Collection (Manassas, VA, USA) and grown as described previously (22, 32) . All other cell lines were obtained from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany): human erythroleukemia K562 cells (ACC 10), human acute myeloic leukemia UT-7 cells (ACC137), human erythroleukemia (HEL) cells (ACC 11), human B-cell precursor leukemia Reh cells (ACC 22), human neuroblastoma SH-SY5Y cells (ACC 209), and mouse erythroleukemia MEL-745A cells (ACC 501). The cells were grown according to the supplier's protocol.
Isolation of hematopoietic progenitor cells from murine fetal liver
Hematopoietic progenitors were isolated from murine fetal liver (e11.5) by magnetic cell sorting using MACS CD117 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the supplier's protocol. In brief, time-phased pregnant heterozygous Wt1 ϩ/Ϫ mice were sacrificed by cervical dislocation. Fetuses with the adhering placentas were removed after laparoscopy and placed in ice-cold Iscove's medium supplemented with 2% fetal bovine serum (FBS). The livers were carefully isolated, and the tails of the embryos were collected for genotyping. The hepatic tissue was minced in a Petri dish using a razor blade. After addition of 1 ml Iscove's medium, the cell aggregates were disrupted by 3 or 4 drawings through a 21-gauge needle. The disrupted tissue was transferred into 14-ml tissue culture tubes and incubated for 5 min on ice to allow larger fragments to settle. The remaining cells were centrifuged for 10 min at 400 g and resuspended at 10 7 cells per 80 l in phosphate-buffered saline, pH 7.2; 0.2% BSA; and 2 mM EDTA. After addition of 20 l CD117 microbeads, the cells were incubated for 15 min on ice. CD117 ϩ cells were isolated by magnetic separation and cultured in Iscove's medium supplemented with 20% BIT 9500 (StemCell Technologies, Vancouver, BC, Canada), 1% glutamate, 40 g/ml low-density lipoprotein, 100 mol/l ␤-mercaptoethanol, and 100 ng/ml stem cell factor. Recombinant human Epo (rhEpo; Epoetin-beta, Roche, GrenzachWyhlen, Germany) was added to the culture medium as indicated.
In vitro progenitor cell assays and benzidine staining
Wt1
ϩ/ϩ , Wt1 ϩ/Ϫ , and Wt1 Ϫ/Ϫ fetal livers, taken at day e11.5 of development, were dissociated in Iscove's medium supplemented with 2% fetal bovine serum as described above. Cell aliquots were counted in a Neubauer chamber, and 1 ϫ 10 5 cells were seeded per well and cultured for 2 days as duplicates in Methocult GF M3434 medium (StemCell Technolo-gies) in a humidified 5% CO 2 atmosphere at 37°C. For the detection of erythroid progenitors, the livers of Wt1 ϩ/ϩ , Wt1 ϩ/Ϫ , and Wt1 Ϫ/Ϫ littermates were dissociated, and hemoglobin-positive cells were detected by benzidine staining after lysis of red blood cells (33) . Hemoglobin-containing cells were counted in a Neubauer chamber.
EMSA
In vitro binding assays were performed with GST-purified Wt1, as described previously (22) . A double-stranded oligonucleotide (oligo Ϫ32/Ϫ8) was chosen on the basis of predicted Wt1 binding sites in the human EpoR promoter [National Center for Biotechnology Information (NCBI) accession no. M76595.1]: 5Ј-GAGTGCTGGCCCCGCCCCCTCGGGG-3Ј and end-labeled with 32 P. Two different base pair mutations were introduced into oligo Ϫ32/Ϫ8 either alone (mutant A, 5Ј-GAGTGCTGGCAACGCCCCCTCGGGG-3Ј; mutant B, 5Ј-GAGTGCTGGCCCCGCAAACTCGGGG-3Ј) or in combination (mutant A/B, 5Ј-GAGTGCTGGCAACGCAAACTCGGGG-3Ј). An unrelated oligonucleotide corresponding to nt Ϫ116/Ϫ87 relative to the transcription start site of the human Epo gene (NCBI M11319.1) served as a negative control (5Ј-TGC-TCTGACCCCGGGTGGCCCCTACCCCTG-3Ј).
Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed in duplicate with freshly prepared cells from murine fetal livers at e11.5 (nϭ8 per experiment) by using a ChIP Assay Kit (17-295; Upstate, Lake Placid, NY, USA). Proteins were cross-linked to the DNA by incubation of the cells with formaldehyde at a final concentration of 0.4%. For immunoprecipitation, antibodies (4 g each) against acetylated histone 3 (06-599; Upstate), Wt1 (C-19), Sp1 (PEP-2), GATA-1 (N-6), STAT5 (H-134), and RNA polymerase II (N-20) were used (all from Santa Cruz Biotechnologies, Santa Cruz, CA, USA). Incubation with no antibody served as a negative control, the "input" sample as a positive control. For analysis of ChIP experiments, the following primer pairs were used to amplify a 330-bp sequence within the murine EpoR promoter (NCBI X53081): 5Ј-TGACCACATTAGC-AAAGCCA-3Ј (forward primer), 5Ј-CCCTGAGTTTGTCCAT-GATG-3Ј (reverse primer). A 253-bp sequence within the murine thrombopoietin receptor (TpoR) promoter (NCBI Z22657.1) was amplified using the following oligonucleotides: 5Ј-AGAGACAGGGACAGGACGT-3Ј (forward primer), 5Ј-AGGGTCTCCCTTTGCCTGT-3Ј (reverse primer).
Plasmids
A 309-bp sequence of the human EpoR promoter (nt Ϫ309 to ntϩ4 relative to the transcription start site; NCBI M76595) was cloned by PCR from genomic DNA using the PCR primers shown in Table 1 . The amplified DNA was ligated into the SacI and HindIII restriction sites of the pGL2 reporter vector (Promega, Mannheim, Germany). Likewise, a 180-bp sequence of the proximal murine EpoR promoter (nt Ϫ180 to ntϩ17 relative to the transcription start site; NCBI M38133) was cloned and ligated into the pGL2 reporter vector. The Wt1 expression constructs (murine Wt1 cDNA ϩ/ϪKTS in pCB6 ϩ ) were kindly provided by Daniel A. Haber (Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, USA) (34) . A PCR-based protocol was applied to introduce site-directed mutations into the predicted Wt1 binding elements within the human and mouse EpoR promoter. The mutant EpoR promoter sequences were ligated into the pGL2 basic reporter vector and verified by automated sequencing (MWG Biotech, Ebersberg, Germany).
Cell transfections and reporter gene assays
K562 and HEK293 cells were transiently cotransfected with the following plasmids using Geneporter2, according to the supplier's protocol (Gene Therapy Systems, PEQLAB, Erlangen, Germany): 100 ng promoter-firefly luciferase plasmid, 125 ng Wt1(ϪKTS), Wt1(ϪKTS) or empty pCB6 ϩ expression constructs, and a Renilla luciferase plasmid for normalization of the transfection efficiencies. The cells were lysed 36 h after transfection, and luciferase activities were measured in a luminometer (Microlite TLX1, MGM Instruments, Hamden, CT, USA) with luciferin (Promega) as a substrate. Values are presented as relative light units, and the results are averages of 5 transfection experiments, each performed in duplicate.
Quantitative RT-PCR analysis of gene expression
Total RNA preparation and first-strand cDNA synthesis were carried out as described previously (35) . A 1:200 volume aliquot of the reaction was taken for PCR quantification with the GeneAmp 5700 Sequence Detection System (PerkinElmer, Applied Biosystems, Foster City, CA, USA) (22, 36) . Primer sequences that were used for PCR amplification are shown in Table 2 . Transcript levels were compared on the basis of differences in the threshold cycles (C t ) values. Only samples with equal levels of GAPDH mRNA (Ϯ 0.5 C t ) were taken into account. Transcript levels of the gene of interest are indicated as the difference between the C t value of H 2 O (background) and the C t value of the respective gene.
Immunoblot
Western blot analysis of Wt1 protein expression in HepG2 cells that had been transfected with Wt1 expression con- Human sense oligo Ϫ309/Ϫ292 5Ј-ATCGAGCTCTTTCCAGGCTGGGAAGAG-3Ј Human antisense oligo ϩ4/Ϫ14 5Ј-CTGAAGCTTTAAGTGGCAGATCCCCGA-3Ј Human/mouse sense oligo mutant A Ϫ32/Ϫ8
5 Ј-GAGTGCTGGCAACGCCCCCTCGGGG-3Ј Human/mouse sense oligo mutant B Ϫ32/Ϫ8
5 Ј-GAGTGCTGGCCCCGCAAACTCGGGG-3Ј Human/mouse sense oligo mutant A/B Ϫ32/Ϫ8
5 Ј-GAGTGCTGGCAACGCAAACTCGGGG-3Ј Mouse sense oligo Ϫ180/Ϫ161 5Ј-CTGGTTTAGGCAGTGGCTGT-3Ј Mouse antisense oligo ϩ17/Ϫ1
5 Ј-CACCTCTCCTTCCCTTTCCT-3Ј structs or with "empty" vector was performed as described elsewhere (22) . A polyclonal anti-Wt1 antibody from rabbit (C-19; Santa Cruz Biotechnology; 1:100 dilution in PBS, 5% Blotto, 0.05% Tween-20) and a goat polyclonal anti-␤-actin antibody (C-11; Santa Cruz Biotechnology; 1:500 dilution) were used for protein detection.
Statistics
ANOVA with Bonferroni test as post hoc test calculations and
Student's t test were performed as indicated to reveal statistical significances. Values of P Ͻ 0.05 were considered statistically significant.
RESULTS
EpoR mRNA is reduced in CD117 ؉ cells from Wt1-deficient murine fetal liver
We first examined whether EpoR expression levels differ in wild-type and Wt1-mutant hematopoietic progenitor cells. For this purpose, CD117 ϩ cells were isolated by magnetic cell sorting from the livers of Wt1
Wt1
ϩ/Ϫ , and Wt1 Ϫ/Ϫ murine embryos (e11.5). EpoR transcripts were significantly reduced by 36 Ϯ 16% in hematopoietic progenitor cells of homozygous Wt1-deficient vs. normal and heterozygous fetal liver (Fig. 1) . No significant differences in EpoR mRNA levels were found between Wt1 ϩ/ϩ and Wt1 ϩ/Ϫ CD117 ϩ cells. To exclude that the lower EpoR mRNA levels resulted from a general down-regulation of gene expression in Wt1
Ϫ/Ϫ cells, we analyzed two other hematopoietic growth factor receptors that are normally expressed during the early stages of murine hematopoiesis. As shown in Fig. 1 
ϩ cells (Fig. 1 ). These findings indicate that Wt1 is required for normal EpoR transcripts in CD117 ϩ hematopoietic precursors from fetal mouse liver. Furthermore, Gata-1 and Sp1 are unlikely to account for the reduced EpoR expression in Wt1-deficient cells. Quantitative analysis of EpoR protein expression could not be performed by Western blot or immunohistochemistry due to nonspecific cross-reactivity with several other proteins, i.e., heat shock protein (HSP) 70 (37) (38) (39) . Flow cytometric analysis using biotinylated rhEpo (Epoetin-beta) failed because of limited sensitivity of the method (data not shown).
Wt1-deficient hematopoietic progenitor cells display a reduced proliferation response to recombinant human erythropoietin
We investigated next whether the lower EpoR levels in Wt1 Ϫ/Ϫ hematopoietic progenitor cells correlate with a reduced susceptibility to recombinant human erythropoietin (rhEpo). For this purpose, CD117 ϩ cells were freshly isolated from the livers of Wt1
, and Wt1 Ϫ/Ϫ murine embryos (C57/B6) at e11.5. In each 
F, forward primer; R, reverse primer.
experiment, progenitors from two Wt1
, and Wt1 Ϫ/Ϫ littermates were seeded at 1 ϫ 10 5 viable cells per well and grown for 48 h in the presence of rhEpo at concentrations between 10 Ϫ5 and 6 U/ml. Figure 2 shows the representative results of one of three independent experiments. The characteristic S-shaped dose-response curve was shifted to higher rhEpo concentrations in Wt1-deficient compared to normal and heterozygous progenitor cell assays. The EC 50 values were 38 mU/ml (Wt1 ϩ/ϩ ), 43 mU/ml (Wt1 ϩ/Ϫ ), and 122 mU/ml (Wt1 Ϫ/Ϫ ) of rhEpo. Cell growth was maximal at rhEpo concentrations above 1 U/ml medium but remained significantly lower in Wt1-deficient than in wild-type and heterozygous hematopoietic progenitors even with 6 U rhEpo/ml medium (Fig. 2) . CD117 ϩ cells failed to grow in the absence of rhEpo, no matter whether they had been obtained from wild-type or Wt1-mutant fetal liver (data not shown). These findings indicate that Wt1 is required for the normal proliferation of murine hematopoietic progenitor cells in response to rhEpo.
In vitro erythroid differentiation is compromised in Wt1
؊/؊ fetal liver cells
In vitro hematopoietic progenitor assays were performed with freshly prepared cells from murine fetal liver (e11.5) to explore whether the reduced proliferation response of Wt1-deficient CD117 ϩ cells to rhEpo would correlate with impaired erythroid differentiation. Because previous studies yielded conflicting results with regard to the colonogenic potential of Wt1 Ϫ/Ϫ vs. Wt1 ϩ/ϩ hematopoietic progenitor cells (7, 10), we applied the same protocol using nonselected murine fetal liver cells. The freshly isolated cells were grown in MethoCult medium supplemented with 3 U rhEpo/ml medium to stimulate differentiation along 
in the colony-forming potential were seen between progenitor cells of Wt1 ϩ/ϩ and Wt1 ϩ/Ϫ embryos (Fig. 3A) . In another set of experiments, hemoglobin staining with benzidine was used as a measure of erythroid differentiation. As shown in Fig. 3B (Fig. 3C) . No significant decrease in EpoR mRNA was seen in the livers of Wt1 ϩ/Ϫ embryos. Hearts were analyzed as a nonhematopoietic tissue that expresses both EpoR und Wt1. Remarkably, EpoR mRNA expression, which was normalized to Gapdh transcripts, was similar in the hearts of Wt1 ϩ/ϩ , Wt1 ϩ/Ϫ , and Wt1 Ϫ/Ϫ embryos at e11.5 (Fig. 3C ).
Wt1 and EpoR are coexpressed in CD117
؉ fetal liver cells and hematopoietic cell lines As a prerequisite for EpoR regulation by Wt1, one would expect that both genes are coexpressed in a population of hematopoietic progenitor cells. To determine the distribution of Wt1 and EpoR in hematopoietic and nonhematopoietic precursors, we isolated CD117 ϩ and CD117
Ϫ cells from the liver of normal mouse embryos (e11.5). The selection procedure was highly reliable, as indicated by the expression of stem cell factor receptor, c-kit, exclusively in CD117 ϩ but not in CD117 Ϫ cells (Fig. 4A) . Importantly, EpoR and Wt1 were coexpressed in CD117 ϩ cells, which represent a population of predominantly hematopoietic progenitors. Their hematopoietic origin is reflected by the significant enrichment of transferrin receptor (Trf-R) mRNA compared to CD117
Ϫ cells (PϽ0.01; Fig. 4A ). In contrast, expression levels of the ubiquitous Sp1 molecule, an established transcriptional activator of the EpoR gene (31, 40) , were significantly higher (PϽ0.05) in CD117 Ϫ vs. CD117 ϩ cells. Wt1 transcripts could not be detected in CD117 Ϫ cells, which expressed the EpoR gene at a similar level as CD117 ϩ progenitors (Fig. 4A ). CD117 (c-kit) is not only present in hematopoietic precursors but also in mesenchymal cells and immature hepatocytes in the fetal liver (41, 42) . To address the relationship between Wt1 and EpoR in a complementary approach, we determined the expression levels of both genes in different hematopoietic and nonhematopoietic cell lines. Remarkably, Wt1 and EpoR transcripts were detected in all hematopoietic cell lines examined, including human erythroleukemia (K562, HEL, UT-7) and leukemia (Reh) cells, as well as murine erythroleukemia (MEL) cells (Fig. 4B) . The only nonhematopoietic cell line that coexpressed both genes at a detectable level were human hepatoma-derived HepG2 cells. All other tested cell lines contained either Wt1 (HEK293 cells) or EpoR mRNA (SH-SY5Y human neuroblastoma cells) only (Fig. 4B) . These results indicate that Wt1 and its proposed molecular target gene, EpoR, are coexpressed in CD117 ϩ cells from murine fetal liver and in different hematopoietic cell lines.
EpoR mRNA is increased by transient expression of the Wt1(؊KTS) protein in HepG2 cells
To examine whether Wt1 activates the expression of the EpoR gene in vitro, HepG2 cells were transiently transfected with different Wt1 expression constructs (4 independent experiments). Human HepG2 cells were chosen because of their higher transfection efficiencies compared to other cell lines. Using a variety of different protocols for the transfection of hematopoietic cells, Wt1 protein could not be increased above the endogenous level in these cells. However, HepG2 cells, which served also as a model for hepatic Epo production (43) , have a low basal expression of both, EpoR and Wt1. EpoR transcripts increased approximately 2-fold within 48 h after transient transfection with the Wt1(ϪKTS) construct compared to cells that had been transfected with "empty" pCB6 ϩ plasmid. In contrast, transfection with the Wt1(ϩKTS) form did not significantly change the endogenous EpoR mRNA content (Fig. 5A) . Transient transfection with Wt1(ϪKTS) and Wt1(ϩKTS) expression constructs resulted in a moderate but significant increase of Wt1 protein in HepG2 cells (Fig. 5B ). These observations indicate that the Wt1(ϪKTS) isoform increases EpoR mRNA in vitro either directly or through indirect mechanisms.
The Wt1(؊KTS) protein binds to the EpoR promoter
EMSAs were performed to explore whether Wt1 protein can bind to the proximal EpoR promoter. On the basis of its sequence similarity with known Wt1-binding sites of other genes, we selected a double-stranded DNA oligonucleotide located between the nucleotides nt Ϫ32 and nt Ϫ8 relative to the transcription start site in the human EpoR promoter, which is also highly conserved in the mouse. As shown in Fig. 6A (left panel), the Wt1(ϪKTS) protein bound to the oligonucleotide Ϫ32/Ϫ8 with higher affinity than the Wt1(ϩKTS) molecule. The two Wt1 proteins did not interact with an oligonucleotide derived from the promoter of the human Epo gene (22), which served as a negative control. Two potential Wt1 motifs within the oligonucleotide Ϫ32/Ϫ8 were analyzed in more detail by introducing mutations to abrogate binding of the Wt1(ϪKTS) protein. As shown in Fig. 6A (right panel) , a double base-pair mutation at positions nt Ϫ22 to nt Ϫ21 in the oligonucleotide (mutant A) did not diminish Wt1(ϪKTS) binding. However, mutations at positions nt Ϫ17 to nt Ϫ15 (mutant B) clearly abolished the DNA binding activity of Wt1(ϪKTS). Consistently, Wt1(ϪKTS) did not bind to an oligonucleotide that contained both mutations in combination (mutant A/B).
ChIP assay experiments were performed to investigate whether Wt1 interacts with the promoter of the EpoR gene in its natural chromosomal context. The experiments were carried out with freshly isolated cells from dissected murine fetal liver (e11.5), which is the primary site of hematopoiesis at this stage of development. As shown in a representative agarose gel (Fig.  6B) , Wt1 bound to the proximal murine EpoR promoter. Likewise, Sp1, Gata-1, and STAT5 also interacted with the EpoR promoter in murine fetal liver cells. In contrast, Wt1, like Gata-1 and STAT5, did not bind to the murine TpoR promoter (Fig. 6B) , which is consistent with our finding of a normal Tpo receptor mRNA expression in Wt1-deficient hematopoietic progenitors (Fig. 1) .
Wt1(؊KTS) protein activates the EpoR promoter
Luciferase-reporter gene assays were performed in HEK293 and K562 erythroleukemia cells to examine whether binding of the Wt1 proteins can activate the EpoR promoter. Therefore, reporter gene constructs, which contained the human and mouse EpoR promoter (lanes 10 and 12) , whereas the affinity for Wt1(ϪKTS) is maintained in mutant A (lane 8). B) Scheme of the murine EpoR 5Ј-untranslated region. Arrow indicates the transcription start site (ϩ1), and the start codon (ATG) is indicated. The position of nucleotides is given relative to the transcription start according to the reference sequence (NCBI X53081). ChIP analysis of protein interaction with the EpoR gene was performed in freshly prepared murine fetal liver cells (e11.5; bottom panel). Control experiments were performed by amplification of a sequence within the murine thrombopoietin receptor (mTpoR) promoter. Panel shows the PCR-amplified products of the immunoprecipitates, which were electrophoresed in a 1.5% agarose gel and stained with ethidium bromide; for better visualization, the gel photograph is presented as a negative of the original. In addition to Wt1, Sp1, GATA-1, and STAT5 did also interact with the EpoR promoter in vivo.
ϩ plasmid, the Wt1(ϪKTS) protein enhanced EpoR promoter activity usually more than 10-fold in both cell lines, as indicated by the significant increase of normalized luciferase activity (PϽ0.001; 5 independent experiments; Fig. 7 ). For comparison, the Wt1(ϩKTS) protein had a minor, though significant, stimulatory effect on EpoR promoter activity in K562, but not in HEK293 cells. Activation of a GC-rich promoter by the Wt1(ϩKTS) protein, which fulfils a presumed role in RNA processing (13) , has been also reported in our earlier study (44) and may reflect functional redundancy of the different Wt1 molecules. To confirm the cis-elements required for stimulation of the EpoR promoter by the Wt1 protein, we introduced the indicated mutations (mutant A/B; Fig. 7A ), which resulted in a loss of Wt1(ϪKTS) binding activity in the EMSA experiments (Fig. 6A) . The mutant human EpoR promoter-reporter construct could not be activated by Wt1(ϪKTS) in HEK293 cells. However, the activity of the mutant reporter construct in K562 cells was slightly increased by Wt1(ϪKTS). Likewise, the mutant murine EpoR promoter-reporter construct was activated by cotransfection of Wt1(ϪKTS) in K562 and HEK293 cells (Fig. 7B, C) . Whether these differences in the susceptibility of the mutant promoter-reporter constructs to stimulation by the Wt1 protein represent cell-typespecific phenomena or point to the existence of yet other, unidentified Wt1 binding cis-elements in the GC-rich EpoR promoter, is currently unknown. In either case, stimulation by Wt1(ϪKTS) was significantly weaker with the mutant vs. wild-type reporter constructs in both cell lines.
DISCUSSION
Herein, we describe the Wilms' tumor suppressor, Wt1, as a novel transcriptional activator of the EpoR gene. This conclusion is supported by the fact that the transcriptionally active Wt1(ϪKTS) isoform stimulates the human and murine EpoR promoter by binding to a GC-rich element in proximity to the transcription start site (Figs. 6 and 7) . Both genes are coexpressed in CD117 ϩ hematopoietic progenitors from fetal mouse liver and in various erythroid cell lines (Fig. 4) . In homozygous Wt1-deficient embryonic mice (e11.5), EpoR expression is significantly reduced in the liver as the primary hematopoietic organ at this stage of development (Fig. 3) . The proliferation of CD117 ϩ progenitors in response to rhEpo and the in vitro erythroid colony-forming potential of murine fetal liver cells (e11.5) are compromised in the absence of Wt1 (Figs. 2  and 3 ). Our results suggest that such a defect could be at least in part due to the lower expression level of EpoR in Wt1-deficient CD117 ϩ cells (Fig. 1) . By demonstrating that Wt1 is required not only for the normal expression of Epo in murine fetal liver (22) but also synergistically activates EpoR expression in hematopoietic progenitor cells, our findings establish the Wt1(ϪKTS) molecule as a transcriptional regulator during hematopoiesis.
Previous work suggests that Wt1 may exert distinct effects on the lineage-specific differentiation of hematopoietic progenitor cells. Thus, Alberta et al. (7) described that murine fetal liver cells lacking Wt1 exhibit an ϳ75% reduction in the proliferation of BFU-E, CFU-E, and CFU-GEMM progenitors (7) . In contrast, King-Underwood et al. (10) reported that Wt1-deficient murine fetal liver cells can reconstitute hematopoiesis following their transplantation into irradiated recipients. However, Wt1-null embryonic stem cells, although contributing to other organ systems, competed poorly with wild-type stem cells in the formation of the hematopoietic system (7). These inconsistent findings could be due to differences in the study design and genetic heterogeneity of the animals used. Because both investigations were performed in different mouse strains (C57/B6 and CBA, respectively), this could indicate that the function of Wt1 during murine hematopoiesis is controlled by additional modifier genes. In support of such a possibility, the phenotype of the developmental abnormalities, i.e., malformation of the spleen, seen in Wt1 Ϫ/Ϫ mice is also dependent on the genetic background of the mutant animals (17) .
Unlike other investigators, who isolated nonselected cells from murine fetal liver (7, 10), we initially selected for CD117 ϩ progenitors. The hematopoietic source of these cells is revealed by their more than 50-fold higher expression level of the Trf-R compared to CD117 Ϫ cells (Fig. 4) . As one major novel finding of this study, we show that the reduced proliferation response of Wt1 Ϫ/Ϫ hematopoietic progenitors to rhEpo is associated with a lower expression rate of EpoR (Fig. 1) . Obviously, the decrease of EpoR mRNA was not due to a general inhibition of gene expression in Wt1-deficient CD117 ϩ cells as the transcript levels of several other hematopoiesis-associated genes, such as TpoR (c-mpl) and G-CSFR, were similar to those in wild-type progenitor cells (Fig. 1) . Interestingly, even in the absence of Wt1, EpoR expression is not completely abrogated, but EpoR transcripts are reduced by ϳ40% in Wt1-deficient hematopoietic progenitor cells. Consistently, murine embryos with targeted inactivation of the Wt1 gene usually develop less severe defects of their hematopoietic system than mice with homozygous lack of EpoR (23, 24, 45) . These results suggest that the transcriptional control of EpoR expression is established with some functional redundancy, thereby allowing other transcription factors to compensate to some extent for the absence of Wt1. Importantly, Sp1 and Gata-1, two previously recognized transcriptional activators of the EpoR gene (29 -31) , were expressed at similar levels in Wt1 ϩ/ϩ , Wt1 ϩ/Ϫ , and Wt1 Ϫ/Ϫ CD117 ϩ cells (Fig. 1) . It appears therefore possible that the two transcription factors maintain a reduced expression rate of EpoR in Wt1 Ϫ/Ϫ progenitor cells. Unfortunately, EpoR expression could not be analyzed at the protein level because of the lack of specific anti-EpoR antibodies (37) (38) (39) and technical limitations of flow cytometry to detect the expected relatively small number of EpoR on the cell surface of immature CD117 ϩ cells isolated from the murine fetal liver (46) .
To confirm the findings obtained with CD117 ϩ progenitor cells, we performed in vitro progenitor assays with fetal liver cells of wild-type and Wt1-deficient mice (C57/B6 strain). Consistently, Wt1 Ϫ/Ϫ fetal liver cells had a significantly reduced colony-forming potential and a lower number of hemoglobin-positive cells than Wt1
ϩ/Ϫ cells (Fig. 3) . Indeed, we did not detect differences in the erythroid colony-forming potential between Wt1 ϩ/Ϫ and Wt1 ϩ/ϩ fetal liver cells. While this observation is in conflict with previous data from another group reporting a reduced colony-forming capacity of Wt1 ϩ/Ϫ murine fetal liver cells (7), it is in accordance with the lack of an obvious hematopoietic disorder in neonatal and adult Wt1 ϩ/Ϫ mice. However, even a small percentage of surface EpoR may suffice to maintain basal proliferative activity (47, 48) . Together, with the finding that forced Wt1 expression is associated with impaired hematopoiesis (8, 49) , our results suggest that a balanced level of Wt1 may be required for the normal differentiation of lineage-committed hematopoietic progenitor cells. Such dose-dependent effect of a transcriptional regulator is also known for other factors involved in hematopoiesis, e.g., GATA-3 (50, 51) .
In addition to validating the role of Wt1 in murine hematopoiesis, our study extends the understanding of the transcriptional regulation of the EpoR gene. So far, GATA-1 and Sp1 have been identified as the major transcriptional regulators of the EpoR gene (29, 31) . During the differentiation of erythroid progenitor cells, GATA-1 is thought to act on EpoR expression in a cell cycle-dependent manner. As previously shown in logarithmically growing Epo-dependent leukemia cells (UT-7 cell line), both EpoR and GATA-1, but not GATA-2 mRNA levels, concomitantly decrease in the G 0 /G 1 phase and later increase in the S und G 2 /M phase. These dynamic changes in EpoR mRNA go in parallel with changes in the binding activity of GATA-1 to the EpoR promoter. It has been speculated that the increase of EpoR mRNA during the resting phase, if induced by growth factor starvation, is dependent on other transcription factors than GATA-1 (52) . In accordance, increased levels of GATA-1 alone are not sufficient to maintain or stabilize the erythroid phenotype during differentiation (53) . Since high levels of EpoR expression in hematopoietic cells apparently do not depend on the level of GATA-1 alone, Wt1 could be the previously postulated additional factor required for activation of the TATA-less EpoR promoter in these cells (31) .
The stage-specific expression of transcription factors during erythroid differentiation needs to be precisely fine-tuned. Interestingly, Wt1 in hematopoietic progenitors itself seems to be regulated by GATA-1 and c-Myb (54, 55) . GATA-1 can transactivate a specific enhancer region 3Ј of the Wt1 gene, and another GATA-1 sensitive enhancer element is located within the third exon of Wt1 (54, 55 ). This suggests that the level of Wt1 in hematopoietic progenitor cells is tightly controlled by a number of other transcription factors, some of which may activate the EpoR gene also through a direct mechanism. So far, our data do not support a role for Wt1 in EpoR expression in nonerythroid tissues, such as the heart (Fig. 3) . Consistently, while Wt1 and EpoR are coexpressed in all hematopoietic cell lines examined in this study, regulation of both genes does not seem to be tightly linked in nonhematopoietic cells (Fig. 4B) . However, given the importance of EpoR in mediating the neuro-and cardioprotective effects of Epo (56, 57) , additional elaborate studies will be necessary to address this issue more in detail. With the present study, we identified the EpoR gene as the first downstream target of Wt1 within the hematopoietic cytokine receptor superfamily. Activation of the EpoR gene by Wt1 may represent an important mechanism in normal murine hematopoiesis. Furthermore, other Wt1 gene targets may additionally contribute to the decreased Epomediated proliferation of Wt1-deficient hematopoietic progenitors.
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